 
                                                                                                    27/08/2024
Breast Cancer StudyStudy Name: A phase 3 randomized, open-label study of Palazestrant (OP-1250) monotherapy vs standard of care for the treatment of ER+, HER2– advanced or metastatic breast cancer following endocrine and CDK 4/6 inhibitor therapy (OPERA-01)Eligibility:Histologically or cytological...
 
                                                                                                     
                                                                                                     
                                                                                                     
                                         
   
   
   
   
     
   
   
  